Evidence map›Paper›PMID 41679925›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Preclinical

Brett A Vaughn, Darren R Veach, Daniela Burnes Vargas, Shin Seo, Blesida Punzalan, Sara S Rinne, Edward K Fung, Hong Xu, Hong-Fen Guo, Guangbin Yang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Emerging Theranostic Radiometals (Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  2. PreclinicalJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Brett A VaughnMolecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, New York, New York.
Darren R VeachDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Daniela Burnes VargasMolecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, New York, New York.
Shin SeoMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Blesida PunzalanMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Sara S RinneMolecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, New York, New York.
Edward K FungDepartment of Medical Physics, Weill Cornell Medicine, New York, New York.
Hong XuDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Hong-Fen GuoDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Guangbin YangOrganic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York; and.
Ouathek OuerfelliOrganic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York; and.
Sebastian E CarrascoLaboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and Rockefeller University, New York, New York.
Samantha St JeanLaboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and Rockefeller University, New York, New York.
Nai-Kong V CheungDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Steven M LarsonMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Sarah M ChealMolecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, New York, New York; smc4002@med.cornell.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Tumor Evolution and Changes in MetabolismP50CA086438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LARSON, STEVEN MARK · 2000 to 2015
$29.9M
DOTA-based pre-targeting of alpha emittersR01CA233896 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHEAL, SARAH MARIE · 2019 to 2023
$3.4M
Organic Synthesis at the Service of Biology and MedicineR50CA243895 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ouathek Ouerfelli · 2019 to 2026
$1.9M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA086438NCI NIH HHS R01 CA233896NCI NIH HHS R50 CA243895
6 · The paper itself

Abstract

The

Indexed as

Colorectal NeoplasmsHeterocyclic Compounds, 1-RingLead RadioisotopesOrganometallic CompoundsRadioimmunotherapyAnimalsCell Line, TumorFemaleHumansMiceMice, NudeTissue DistributionXenograft Model Antitumor Assays1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidHeterocyclic Compounds, 1-RingLead-203Lead-212Lead RadioisotopesOrganometallic Compounds212Pbcolorectal cancerglycoprotein A33pretargeted radioimmunotherapytargeted α-therapy

Identifiers

PMID41679925
PMCPMC13138092

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.